Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...

Antibody-drug conjugates (ADCs) are fusions of therapeutic drugs and antibodies conjugated by a linker, designed to deliver a therapeutic payload to cells expressing the target antigen. By delivering ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...

Purpose: The permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions is described. Methods: Thirteen cytotoxic agents were prepared at the highest concentrations ...

I have been a cancer doctor for 40 years and have seen our treatments evolve to embrace precision medicine and immunotherapy, which can be less harmful to patients than conventional forms of ...

In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs.

Since the landmark 2019 approval of Enhertu, the antibody-drug conjugate (ADC) drug that quickly became a blockbuster breast cancer therapy—with global sales surpassing $1.6 billion in 2022—industry ...

Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug ...